ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0738

Therapeutic Effects of Oral Chinese Patent Medicine on Knee Osteoarthritis

Weiheng Chen1, Mengge Song1, Yan Jia1, Jigao Sun1, Yan Zhao2, Zhipeng Xue3, Qianglong Chen2, xiangrong Zeng2 and Chenchen Wang4, 1The Third Affiliated Hospital of Beijing University of Chinese Medicine, Beijing, China (People's Republic), 22Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, China (People's Republic), 31The Third Affiliated Hospital of Beijing University of Chinese Medicine, Beijing, China;, Beijing, China (People's Republic), 4Tufts Medical Center, Boston, MA

Meeting: ACR Convergence 2021

Keywords: Osteoarthritis, pain, Patient reported outcomes, Therapy, alternative, Therapy, complementary

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: Osteoarthritis – Clinical Poster II (0723–0738)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Oral Chinese patent medicine (CPM) has been deemed to have analgesic and anti-inflammatory effects and is widely used as the first-line treatment for osteoarthritis (OA) in Asia countries. Despite this enthusiastic use of CPM for knee OA, its clinical efficacy remains unclear. We conducted an updated review to determine the effects of these therapies to inform clinical practice.

Methods: We performed a comprehensive search on PubMed, Cochrane Library, EMBASE, Biomedical Databases, National Knowledge Infrastructure, Wanfang, and VIP through May 2021. We included randomized controlled trials (RCTs) of oral CPM therapies as the first-line treatment in adults with knee OA. Knee OA was defined by the American College of Rheumatology criteria or the Chinese orthopedic association criteria. We also accepted the composite outcome criteria developed by the Chinese National Institute of Rheumatology as an endpoint (total effective rate, between 0-100%, higher score = better outcome), which assesses the overall pain, physical function and wellness. We extracted information on study characteristics, population characteristics, type, duration, frequency of interventions, and outcomes. Study quality was assessed in RevMan5.3 software using the Cochrane Risk of Bias Tool. The differences between treatment groups were reported as mean change or percentage improvement (P-value).

Results: We identified 1096 potentially relevant studies. Eighteen with a total of 2474 subjects (59% female, mean age = 59 years, mean pain duration = 3 years) met eligibility criteria. Seventeen studies were conducted in China and one in Thailand. Table 1 summarized the eighteen RCTs concerned with the effectiveness of oral CPMs for knee OA. Six types of oral CPMs including Jintiange Capsule, Jinwu Gutong Capsule, Zhuanggu Guanjie Capsule, Biqi Capsule, Xianling Gubao Capsule and Duhuo Jisheng Pill were prescribed as the first-line treatment based on the syndrome differentiation. The treatment varied duration from one to three times per day and lengths of the treatment ranged from 4 to 24 weeks. The control group treatments included oral non-steroidal anti-inflammatory drugs (17 studies) and placebo (1 study). Ten studies showed significant pain relief compared to the controls (std, Mean Difference [SMD] = -0.50; 95% CI, -0.86 to -0.13; p< 0.05). Thirteen studies reported a significant improvement in overall clinical symptoms on both pain and function (RR = 1.15; 95% CI, 1.09 to1.22; p< 0.00001). There were no significant differences in Lequesne index between the groups in six studies (MD = -1.11; 95% CI, -2.57 to 0.34; p=0.13). No serious adverse events occurred. Constipation was the most common adverse reaction in the oral CPM group, followed by dizziness, nausea, stomach discomfort and rash, and the incidence of adverse events was significantly lower than the controls.

Conclusion: This review showed promising results for oral CPM that is a safe and potential beneficial effects for knee OA. Further high-quality randomized controlled trials with longer follow-up periods are warranted.


Disclosures: W. Chen, None; M. Song, None; Y. Jia, None; J. Sun, None; Y. Zhao, None; Z. Xue, None; Q. Chen, None; x. Zeng, None; C. Wang, None.

To cite this abstract in AMA style:

Chen W, Song M, Jia Y, Sun J, Zhao Y, Xue Z, Chen Q, Zeng x, Wang C. Therapeutic Effects of Oral Chinese Patent Medicine on Knee Osteoarthritis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/therapeutic-effects-of-oral-chinese-patent-medicine-on-knee-osteoarthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/therapeutic-effects-of-oral-chinese-patent-medicine-on-knee-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology